parsaclisib – Patient Worthy

Source: Pixabay

NDA Withdrawn for Parsaclisib for MCL, MZL, Follicular Lymphoma

Post author:Kendall Mason
Post published:February 4, 2022
Post category:Follicular lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma

Incyte has withdrawn its New Drug Application (NDA) for parsaclisib, which is an investigational treatment for various types of lymphoma, including relapsed/refractory mantle cell lymphoma (MCL), follicular lymphoma, and marginal…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More